BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.
AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the ...
The City of Odessa announced Phase 2 of a waterline replacement project and roadway reconstruction on N. County Road West has started.
BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a ...
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to prioritize ...
Phase 2 trial results show XPro™ benefits cognition in certain early Alzheimer's patients, pending further data analysis and FDA designation. INmune Bio Inc. announced results from its Phase 2 MINDFuL ...
A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301). Background: Response rates (55-65%) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results